breast cancer
Conditions
Interventions
Group A:Mitoxantrone hydrochloride tracer
Group B:Methylene blue
Sponsors
The First Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Female patients aged 18-70 (including 18 and 70 years old); (2) Preoperative pathology confirmed invasive breast cancer or ductal Carcinoma in situ; (3) Clinical T1/T2 (maximum tumor diameter = 5cm) before neoadjuvant chemotherapy; (4) Patients with clinical cN0 and cN1 before neoadjuvant chemotherapy; (5) There is no clinical or imaging basis for distant metastasis; (6) Plan to perform subcutaneous glandular resection of the nipple areola complex with preservation of the nipple; (7) BMI<40 kg/m2; (8) Patients who are allowed to undergo simultaneous endoscopic breast augmentation on the opposite breast; (9) Breast volume below average; (10) Able and willing to sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients who meet any of the following exclusion criteria are excluded: Oncology: 1. Tumor mass with a diameter greater than 5cm; 2. Late tumor stage (such as cN2/cN3 or patients with inflammatory breast cancer); 3. Skin/chest wall invasion; 4. Individuals with a high risk of recurrence (based on multidisciplinary evidence) Reconstruction: 1. Age>70 years old; 2. BMI is more than 40kg/m2 (there are many other complications, such as diabetes, hypertension, and BMI alone is not a Contraindication); 3. The patient has severe illness before surgery, poor overall condition, and cannot tolerate surgery; 4. Immune dysfunction; 5. HbA1c greater than 7.5%; 6. The patient has a long-term history of smoking (2) If the patient has a history of radiotherapy after breast conserving surgery for breast cancer, pregnancy and lactation, known patients with anthraquinone allergy, patients with alcohol or sedative drug dependence, patients with mental illness, patients who have used the test drug in the past, and any patients who participated in any other clinical trial within 3 months before the study. Any breast cancer patients who plan to be pregnant during the trial or within 6 months after the study, as well as those who are participating in other clinical studies and may have an impact on participation in this trial, should also be excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Validity of Sentinel lymph node biopsy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time for local skin blue staining and fading;Safety indicators; | — |
Countries
China
Contacts
Public ContactFan Linjun/ Zeng Lingjuan
The First Affiliated Hospital of the Army Medical University
Outcome results
None listed